pharmaphorum

JANUARY 29, 2021

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. Zinc fingers. billion in funding.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Drug Discovery World

APRIL 3, 2023

From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. Additionally, the intractability of some targets with alternative ligand technologies means ligands simply cannot be developed to some targets, such as toxic or non-immunogenic targets.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

World of DTC Marketing

JANUARY 31, 2021

I always have pointed instances in which pharma puts Wall Street first and patients second. Here are some of her key points from the report: 1ne: In just 10 years, the number of large, international pharmaceutical companies decreased six-fold,from60 to only 10. In pharma R&D returns have declined to 1.8 percent from 2018.

In-Vivo 187

In-Vivo Generic Drugs Gene Therapy Drugs 187

XTalks

OCTOBER 1, 2020

To gain insight into the motivations, steps and experiences involved in an academia to industry — or vice versa — transition, Xtalks spoke to several leading scientists and entrepreneurs in pharma and biotech who successfully transitioned from academic positions to leadership roles in industry settings. Motivations for Transition.

Scientist 52

Scientist In-Vitro Research Life Science 52